SV

Street Verdict

Analyst Scorecard

A record of what Ganesh Dongre said publicly, with the source. Not advice.

“Recommends buying Natco Pharma Ltd (NATCOPHARM) in the range of ₹790-800, setting a target price of ₹840 with a stop loss at ₹770. This call is for the near term, following a stock market holiday.”

Ganesh Dongre’s track record (trackable calls only): 327 graded calls · 95% CI 33–44%

Natco Pharma LtdBullishCalled 30 Mar 2025Graded 07 Apr 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

Entry zone: ₹790–₹800. The call starts at the first close that comes into it.

Target ₹840, stop ₹770, as stated.

No time frame is stated, so it is tracked until a close reaches ₹840 or ₹770: there is no fixed window.

The stop ₹770 was reached on a close before the target ₹840. Miss.

The grader’s working: R3 TRADE_SETUP: entered ₹798.4 on 2025-04-01 (stated entry ₹790–800 zone, ZONE entry, filled); stop ₹770 breached at close ₹759.6 on 2025-04-07. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.

Tracking Natco Pharma Ltd since this call

1-year tracking window
Read the original articleSee Ganesh Dongre’s full track record